French study reviews new Drug's impact on debilitating muscle disease
NCT ID NCT06815133
Summary
This study is reviewing past medical records to understand how well the drug zilucoplan worked for 55 French patients with myasthenia gravis, a disease that causes severe muscle weakness. Researchers are looking at whether the treatment improved patients' daily function, muscle strength, and quality of life over three to six months, while also checking for side effects. The goal is to gather real-world evidence on this treatment's benefits and safety for managing this chronic condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU NICE
RECRUITINGNice, Alpes Maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.